| DB ID | MyCo_7229 |
| Title | Clinical evaluation of two different (1,3)-ß-d-glucan assays for diagnosis of invasive fungal diseases: A retrospective cohort study |
| Year | 2020 |
| PMID | 33156525 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The ethical approval was provided by the Ethics Committee of JUH (Reg. No.: 2019-1354). Due to the retrospective nature of the study, the need of an informed consent was waived by the Ethics Committee. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | This retrospective cohort study was performed at Jena University Hospital (JUH), Germany, between November 2018 and March 2019, included 109 patients with clinical suspicion of IFD. Patients with clinical suspicion of any IFD, in whom at least one GT was performed, were included. Clinical indication to perform a BDG sample was recommended by a specialist of the Institute of Infectious Diseases of the JUH during daily clinic-wide consultations and during weekly antibiotic stewardship visits at the intensive care units. |
| Cohort No. | 109 |
| Age Group | None |
| P Value | None |
| Sensitivity | 54.80% |
| Specificity | 93.30% |
| Positive Predictive Value | 81.00% |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive fungal diseases (IFDs) are life-threatening infections with overall 30-day mortality rates of approximately 40 %, rising to 50-80 % in severely immunocompromised or critically ill patients with septic shock. The most common pathogens causing IFDs in Germany are Candida spp., followed by Aspergillus spp. and Mucorales spp.. Reliable and early diagnosis of IFD is the central challenge in routine clinical practice. However, due to unspecific clinical symptoms and limited diagnostic approaches, the diagnosis of IFDs is often delayed or even missed. In fact, at least 50 % of invasive candidiasis cases remain blood culture negative, and prospective autopsy studies showed that the diagnosis of invasive aspergillosis is frequently missed in critically ill patients. Microbiological culture of sterile sites or histopathological examination are necessary for a confirmatory diagnosis of IFD. Although invasive diagnostic methods remain the gold standard, non-invasive diagnostics are of particular interest for daily routine. Currently, there are a number of serological biomarkers (e.g., Aspergillus galactomannan, Candida mannan/anti-mannan antibodies, and (1,3)-ß-D-glucan [BDG]) utilized in the diagnosis of IFDs. |
| Technique | Analytic |
| Analysis Method | β-Glucan test (GT) |
| ELISA kits | None |
| Assay Data | FDA- Fungitell® assay (Associates of Cape Cod, Falmouth - USA) |
| Validation Techniques used | β-Glucan test (GT) |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
